Sponsors / MLYS
MLYS

Mineralys Therapeutics Inc.

Company identity checked against sources

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
6Trials in this database
12Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled HypertensionNCT05001945MLYSPhase 2Completed2022-09-07Actual
A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication RegimenNCT05769608MLYSPhase 2Completed2025-01-15Actual
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With HypertensionNCT05968430MLYSPhase 3Active not recruiting2025-12-30Actual
Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With AlbuminuriaNCT06150924MLYSPhase 2Completed2025-02-27Actual
Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant HypertensionNCT06153693MLYSPhase 3Completed2024-12-10Actual
A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and HypertensionNCT06785454MLYSPhase 2Completed2025-12-17Actual

Latest recorded trial changes

Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria

NCT06150924 · Mineralys Therapeutics Inc.

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Placebo-adjusted change from baseline in automated office blood pressure (AOBP) systolic blood pressure (SBP) at Week 4 Measure: Incidence and severity of adverse events (AEs)

+ After

Measure: Placebo-adjusted Change From Baseline in Automated Office Blood Pressure (AOBP) Systolic Blood Pressure (SBP) at Week 4

Check registry source
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

NCT05968430 · Mineralys Therapeutics Inc.

· 4 fields changed

Participant count type changed

− Before

Estimated

+ After

Actual

Enrollment · participant count changed

− Before

1400 participants (planned)

+ After

1076 participants (actual)

Completion date type changed

− Before

Estimated

+ After

Actual

Primary completion date changed

− Before

Dec 2025

+ After

30 Dec 2025

Check registry source
A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension

NCT06785454 · Mineralys Therapeutics Inc.

· 4 fields changed

Participant count type changed

− Before

Estimated

+ After

Actual

Enrollment · participant count changed

− Before

40 participants (planned)

+ After

48 participants (actual)

Primary completion date changed

− Before

Oct 2025

+ After

Dec 2025

Recruitment status changed

− Before

Recruiting

+ After

Active not recruiting

Check registry source